Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biological Chemistry
Roche, Oryzon Form Epigenetics Pact
by Lisa M. Jarvis
April 14, 2014
| A version of this story appeared in
Volume 92, Issue 15
Roche will pay Oryzon Genomics up to $21 million in up-front and near-term payments as part of a pact to develop drugs that block lysine-specific demethylase-1 (LSD1), an epigenetic target that regulates gene expression. Under the deal, Roche will take the reins in further developing the Spanish firm’s lead molecule, ORY-1001, which is in Phase I/IIa studies as a treatment for acute myeloid leukemia. Roche also gains the rights to two patent families related to LSD1. The companies will work together to better understand how LSD1 inhibitors can be used to treat cancer.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X